Monday, November 16, 2026 Vol. I · No. 4
Business · Via CNBC

J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences

Johnson & Johnson will acquire Ollin for $2.2 ‌billion upfront, with the potential for milestone payments of up to about $1.13 ⁠billion, the drugmaker said.

This is a brief. The reporting belongs to CNBC — read the complete story, with full context and credits, at the source.

Read the full story at CNBC ↗

cnbc.com

More from the Business desk